OrbiMed’s Advaxis Inc ADXS Stock Holding History

OrbiMed’s Portfolio ADXS Stock Details ADXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-29,693	Closed	-$3.6M	–	154
2016 Q2	$3.6M	Sell	29,693 -12,747	-30%	-$1.63M	0.04%	115
2016 Q1	$5.75M	Hold	42,440	–	–	0.06%	111
2015 Q4	$6.4M	Hold	42,440	–	–	0.06%	104
2015 Q3	$6.51M	Sell	42,440 -7,900	-16%	-$1.91M	0.07%	105
2015 Q2	$15.4M	Buy	50,340 +21,667	+76%	+$6.85M	0.13%	91
2015 Q1	$6.21M	Buy	+28,673	New	+$4.41M	0.05%	115

Other funds holding ADXS

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's ADXS Position: Q3 2016 in Review

OrbiMed sold out of Advaxis Inc (ADXS) in Q3 2016, closing a stake of 29,693 shares — an estimated $3.6M sold.

OrbiMed first reported a position in ADXS in Q1 2015 and held it in 6 quarters. The position peaked at $15.4M in Q2 2015. 100 funds tracked by Wall St. Rank hold ADXS as of Q3 2016.

OrbiMed reported no remaining Advaxis Inc position as of Q3 2016 after selling out during the quarter.
OrbiMed sold 29,693 Advaxis Inc shares in Q3 2016, an estimated $3.6M.
OrbiMed first reported a position in Advaxis Inc in Q1 2015 and held it in 6 quarters.
OrbiMed's Advaxis Inc position peaked at $15.4M in Q2 2015.
100 funds tracked by Wall St. Rank held Advaxis Inc as of Q3 2016.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.